AC
RNTX

Annandale Capital’s Rein Therapeutics RNTX Stock Holding History

Annandale Capital’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16K Hold
15,026
– – ﹤0.01% 128
2026
Q1 		$20K Hold
15,026
– – ﹤0.01% 121
2025
Q4 		$17K Buy
+15,026
New +$20.7K ﹤0.01% 127

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Annandale Capital's RNTX Position: Q2 2026 in Review

Annandale Capital held its Rein Therapeutics (RNTX) position steady in Q2 2026 at 15,026 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #128.

Annandale Capital first reported a position in RNTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $20K in Q1 2026. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Annandale Capital held 15,026 shares of Rein Therapeutics worth $16K as of Q2 2026.
  • Annandale Capital left its Rein Therapeutics share count unchanged in Q2 2026.
  • Rein Therapeutics made up ﹤0.01% of Annandale Capital's portfolio in Q2 2026, its #128 holding.
  • Annandale Capital first reported a position in Rein Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Annandale Capital's Rein Therapeutics position peaked at $20K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Annandale Capital's 13F filing for Q2 2026, filed 13 Aug 2026.